2. Tarantino, P., Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy, 2021. 2: p. 139-155. 3. Drebin, J.A., et al., Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal ...
Immunotherapy is also being investigated in the HER2+ subtype, through immune-checkpoint inhibition, cancer vaccines and adoptive-cell therapies. Overall, the enlarging arsenal of promising anti-HER2 compounds is expected to deliver significant improvements in the prognosis of both early and advanced ...
参考文献 [1]https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl [2]https://www.oncokb.org/gene/ERBB2 [3]Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers 2018; 10 ...
曲妥珠单抗生物类似物:与新型研发的HER2靶向抗体不同,曲妥珠单抗生物类似物是由活细胞形成的生物制剂,具有与原产品相似的药代动力学和药效学特性。目前FDA批准了五种曲妥珠单抗生物类似物进入美国市场,其他药物正在开发中(见相关链接: https://www.fda.gov/dr...
[9] Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. An...
[44]Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935. [45]Skidmore L, Sakamuri S, Knudsen NA, et al. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cance...
J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17, 2235–2249 (1998). Article CAS Google Scholar Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast ...
et al. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study[J]. Anticancer Drugs. 2020 ...
for the use of anti-HER2 agents alone and in combination, examines the latest advances in HER2-targeted drugs and how they may be best applied in clinical practice, and provides guidance on optimal sequencing of the growing array of therapeutic options for HER2-positive breast cancer.doi...
Biologics: Targets & Therapy Dovepress open access to scientific and medical research Open Access Full Text Article HER2 breast cancer therapies: a review review Conleth G Murphy Shanu Modi Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY,...